MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.270
-0.070
-1.61%
After Hours: 4.270 0 0.00% 16:31 09/24 EDT
OPEN
4.340
PREV CLOSE
4.340
HIGH
4.450
LOW
4.110
VOLUME
221.18K
TURNOVER
--
52 WEEK HIGH
12.20
52 WEEK LOW
3.210
MARKET CAP
82.97M
P/E (TTM)
-2.6764
1D
5D
1M
3M
1Y
5Y
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indep...
GlobeNewswire · 09/13 12:05
TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner...
GlobeNewswire · 09/07 12:05
TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments
Sarcoma is not one of the many cancers that reaches top billing in the discussion of cancer research. 
Benzinga · 09/07 11:29
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indep...
GlobeNewswire · 09/02 12:05
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
BRIEF-Tracon Pharmaceuticals Posts Quarterly Loss Per Share Of $0.58
reuters.com · 08/11 20:31
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
- Trial to Continue as PlannedSAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizin...
GlobeNewswire · 08/09 12:05
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner...
GlobeNewswire · 08/03 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TCON. Analyze the recent business situations of TRACON Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TCON stock price target is 11.86 with a high estimate of 15.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 9.23M
% Owned: 47.50%
Shares Outstanding: 19.43M
TypeInstitutionsShares
Increased
6
66.86K
New
7
217.27K
Decreased
14
294.99K
Sold Out
5
165.18K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Charles Theuer
Chief Financial Officer/Chief Accounting Officer
Scott Brown
Other
Mark Wiggins
Independent Director
Lisa Johnson-pratt
Independent Director
William LaRue
Independent Director
Martin Mattingly
Independent Director
Saundra Pelletier
Independent Director
J. Rainer Twiford
Independent Director
Stephen Worland
No Data
About TCON
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.